GFAP Mutation Impacts in Neurodegenerative Conditions

Glial fibrillary acidic protein (GFAP) is an intermediate filament protein fundamental to astrocyte architecture and function. Heterozygous mutations in the GFAP gene underlie Alexander disease, a spectrum of neurodegenerative conditions characterised by astrocyte dysfunction, protein aggregation and non-cell-autonomous neuronal injury. Mutant GFAP misassembles into aberrant filaments, leading to the formation of Rosenthal fibres—cytoplasmic inclusions enriched in small heat-shock proteins and ubiquitinated proteins. These aggregates disrupt proteostasis, cytoskeletal integrity and mechanotransduction pathways, provoke chronic stress responses and alter extracellular matrix composition. Consequent changes in tissue stiffness, signalling cascades such as Hippo and STAT3, and post-translational modifications further exacerbate astrocyte pathology, impair neural development and provoke downstream myelination defects. Emerging genotype–phenotype correlations inform clinical variability across infantile, juvenile and adult-onset forms, while advances in human induced pluripotent stem-cell models reveal early developmental perturbations. Together, these insights establish GFAP mutation as a critical driver of astrocyte-mediated neurodegeneration and highlight new avenues for targeted intervention.

Research from Nature Portfolio

A systematic meta-analysis of GFAP variants assembled over five hundred missense changes, revealing that arginine substitutions predominate and are chiefly de novo in early-onset cases, with defective splicing modulating age at onset. This work clarified previously obscure genotype–phenotype relationships and suggested subtle mechanisms influencing clinical expressivity.

Studies of mechanosensitive signalling have demonstrated that GFAP overexpression and mutation elevate tissue stiffness and activate the Hippo pathway, driving upregulation of A-type lamins. Genetic modulation of key pathway components ameliorated behavioural deficits and non-cell-autonomous neurodegeneration in Alexander disease models, thereby uncovering altered mechanotransduction as a critical pathogenic cascade.

GFAP Mutation Impacts in Neurodegenerative Conditions publication trend

The graph below shows the total number of articles in gfap mutation impacts in neurodegenerative conditions across all publications each year (not limited to Nature Index journals).

Technical terms

GFAP: An intermediate filament protein expressed by astrocytes that maintains cytoskeletal architecture.

Alexander disease: A rare, usually progressive neurodegenerative disorder caused by dominant GFAP mutations.

Astrocyte: A glial cell type in the central nervous system that supports neuronal function and homeostasis.

Rosenthal fibres: Intracellular aggregates of GFAP and chaperones characteristic of Alexander disease astrocytes.

Induced pluripotent stem cell (iPSC): A somatic cell reprogrammed to a pluripotent state, capable of differentiating into various cell types.

Single-cell RNA sequencing (scRNA-seq): A method to profile gene expression at the resolution of individual cells.

Mechanotransduction: The process by which cells convert mechanical stimuli into biochemical signals.

Post-translational modification: The covalent alteration of a protein after its synthesis, such as phosphorylation or proteolytic cleavage.

References

1. Aberrant neurodevelopment in human iPS cell‐derived models of Alexander disease. Glia (2024).
2. STAT3 Drives GFAP Accumulation and Astrocyte Pathology in a Mouse Model of Alexander Disease. Cells (2023).
3. A systematic review and meta-analysis of GFAP gene variants in Alexander disease. Scientific Reports (2024).
4. Site-specific phosphorylation and caspase cleavage of GFAP are new markers of Alexander disease severity. eLife (2019).
5. Tissue and cellular rigidity and mechanosensitive signaling activation in Alexander disease. Nature Communications (2018).